2024-05-09 07:14:14 ET
More on Charles River Laboratories
- Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'
- Charles River Laboratories International, Inc. (CRL) Q4 2023 Earnings Call Transcript
- Charles River Laboratories Q1 2024 Earnings Preview
- Charles River, Axovia to collaborate on gene therapy development
- Seeking Alpha’s Quant Rating on Charles River Laboratories
Read the full article on Seeking Alpha
For further details see:
Charles River Laboratories Non-GAAP EPS of $2.27 beats by $0.21, revenue of $1.01B beats by $16.54M